Sanofi-Aventis announced its cancer drug candidate iniparib failed in a late-stage clinical trial. Other pharmaceutical companies have also experienced recent setbacks as they scramble to bolster their pipelines ahead of the pa…
Lpath focuses on developing therapeutics that target bioactive lipids for treating a range of human diseases, including cancer and diseases that cause blindness. Its promising drugs have attracted attention — and lots of money…
A New York City health code regulation set to go into effect on Jan. 1 would have added some disturbing images to the Big Apple’s glittering background of advertising: Hideously accurate ads depicting the results of smoking. Bu…
The U.S. biotech is holding an analyst and investor meeting focused on the commercial potential of its multiple sclerosis drug Campath. The goal: to convince Paris-based Sanofi-Aventis to raise its hostile takeover offer in a b…
As pet cancer increases and pricier treatments become available, the cost of keeping a pet healthy is on the rise. DailyFinance writer Jonathan Berr shares the story of his family dog Ruby’s bout with cancer. How much are you w…